Tirzepatide
A peptide. Sticks to two receptors. Research only. Not a protocol.
Simple words
Your gut releases more than one “I’m full” peptide after food. GLP-1 is one. GIP is another. A receptor is a protein on a cell that a peptide can stick to.
What it is
Tirzepatide is a lab chain that can stick to both the GLP-1 receptor and the GIP receptor. Semaglutide only does GLP-1. That is the whole difference people mean when they say “two receptors.”
The medicine name is Mounjaro / Zepbound. Those are approved drugs. A research vial is not the pharmacy pen.
What researchers studied
Ania Jastreboff and colleagues ran SURMOUNT-1 (New England Journal of Medicine, 2022). Adults with obesity, no diabetes. People on tirzepatide lost more weight than placebo. Stomach side effects were the main complaint.
SURPASS trials tested it for type 2 diabetes. Blood sugar went down. Again: that is the approved product in a trial, not a random vial.
Papers
Jastreboff et al., 2022 — SURMOUNT-1. Weight in adults with obesity. New England Journal of Medicine.
Frías et al., 2021 — SURPASS-2. Tirzepatide vs semaglutide in type 2 diabetes. New England Journal of Medicine.
What this is not
Not “semaglutide but magic.” It is one chain, two receptors. This page does not tell you how much to take.
Related: semaglutide · retatrutide